Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

Update on the Regulatory Strategy for Belinostat in PTCL

COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (Peripheral T-Celle Lymphoma). This pivotal trial is to enrol approximately 120 patients and is to begin in Q4 2008. In June Fast Track designation was granted for the development of belinostat in this indication which supports TopoTarget's rapid market entry strategy. There is currently no standard therapy approved for PTCL.

"This is very good news. We can now move belinostat into a pivotal phase III. With the SPA in place we have agreed on a design for our pivotal phase III trial with the FDA which will begin in Q4 of this year. In addition with the FDA's Fast Track designation received in June for the PTCL indication we can continue with our strategy of rapid market entry for belinostat in an area with a high unmet medical need." Said Professor, Peter Buhl Jensen, MD, CEO of TopoTarget.

Design

The phase III trial is an open-label, multicenter, single arm efficacy and safety trial in patients with relapsed or refractory peripheral T-cell lymphoma who have failed at least one prior systemic therapy. Approximately 120 patients (100 evaluable patients) will be enrolled. Patients will be treated with 1000 mg/m2 belinostat administered as a 30 minute IV infusion on days 1-5 of every 3-week cycle until there is disease progression or unmanageable treatment-related toxicities.

Rational

Belinostat is a small molecule class I and II histone deacetylase inhibitor (HDACi). HDACi's modulate gene expression within tumor cells, including tumor suppressor genes, leading to G1 and G2/M cell cycle arrest, induction of apoptosis (programmed cell death), inhibition of angiogenesis, immune modulation, and promotion of cellular differentiation. Clinic
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... release its second quarter 2014 financial results at the ... 2014. A live conference call and webcast will be hosted ... day. Interested investors and others may participate ... +1 212-231-2900 (international), conference ID#21728775. A replay of the webcast ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... estimated at USD 161,056.5 million in 2014 and is ... 2014 to 2020, to reach an estimated value of ... market is witnessing a significant growth due to the ...
Breaking Biology Technology:String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Wis. - The Potawatomi Business Development Corp. ... Wisconsin information technology firm OneProspect Technologies , and ... ,OneProspect, which had been a business division of the ... the Forest County Potawatomi Community. In January of 2006, ...
... - Since its inception, the Wisconsin Manufacturing Extension ... mid-size manufacturers get lean and mean. Now, the organization ... manufacturers grow, and that includes businesses in the biotechnology ... recently won the Wisconsin's top economic development award, is ...
... technology expenditures of a business. The promise of package ... with a standardized, integrated system, built on processes based ... is combined with promises of a fast implementation and ... package is released. The popularity of package software has ...
Cached Biology Technology:Manufacturing partnership will move into biotech and biomedical spaces 2Manufacturing partnership will move into biotech and biomedical spaces 3Five steps to buying the right package software 2Five steps to buying the right package software 3Five steps to buying the right package software 4Five steps to buying the right package software 5Five steps to buying the right package software 6Five steps to buying the right package software 7
(Date:7/28/2014)... have seen an increase in so-called "nuisance flooding"--which causes ... drains and compromised infrastructure--are on the East Coast, according ... flooding, caused by rising sea levels, has increased on ... since the 1960s. , The report, Sea Level Rise ... also finds Annapolis and Baltimore, Maryland, lead the list ...
(Date:7/28/2014)... bug hunter, but the target of his work consists ... with special methods and instruments. Benjamin Hause, an assistant ... at Kansas State University, recently published an article about ... an important find in the United States. , "We ... what it was," Hause said. "We used next-generation sequencing ...
(Date:7/28/2014)... A powerful new tool that can help advance ... green and renewable bioenergy, has been developed by ... Joint BioEnergy Institute (JBEI), a multi-institutional partnership led ... JBEI researchers have developed an assay that enables ... nucleotide sugar transporters, critical components in the biosynthesis ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3How sweet it is 2How sweet it is 3
... in early childhood significantly contributes to lower performances on ... according to researchers at Duke University and North Carolina ... between lead exposure and test performance, with the effects ... the high end to the low end of the ...
... , PORTOLA VALLEY, Calif., Oct. 19 Spectros, developer ... which shed light on life-threatening diseases, announced today that ... T-Stat® VLS Tissue Oximeter and Sensors. The markets ... Luxembourg (Benelux), Suriname, Italy, France, Spain, Portugal, Poland, Greece, ...
... PASADENA, Calif.Scientists at the California Institute of Technology (Caltech) ... simulate the "visual" experience of a blind person who ... an artificial retina. An artificial retina consists of a ... that directly stimulate retinal nerve cells. It is hoped ...
Cached Biology News:Children's blood lead levels linked to lower test scores 2Spectros Signs New International Distribution Deals 2Caltech scientists create robot surrogate for blind persons in testing visual prostheses 2Caltech scientists create robot surrogate for blind persons in testing visual prostheses 3
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
TAR DNA binding protein...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: